1.3556
price up icon2.27%   0.0356
 
loading
Hoth Therapeutics Inc stock is traded at $1.3556, with a volume of 296.50K. It is up +2.27% in the last 24 hours and up +10.20% over the past month. Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
See More
Previous Close:
$1.32
Open:
$1.31
24h Volume:
296.50K
Relative Volume:
0.28
Market Cap:
$17.83M
Revenue:
-
Net Income/Loss:
$-7.51M
P/E Ratio:
-1.027
EPS:
-1.32
Net Cash Flow:
$-8.02M
1W Performance:
+0.75%
1M Performance:
+10.20%
6M Performance:
-8.16%
1Y Performance:
+38.90%
1-Day Range:
Value
$1.28
$1.40
1-Week Range:
Value
$1.2333
$1.40
52-Week Range:
Value
$0.58
$3.80

Hoth Therapeutics Inc Stock (HOTH) Company Profile

Name
Name
Hoth Therapeutics Inc
Name
Phone
(646)756-2997
Name
Address
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
Name
Employee
3
Name
Twitter
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
HOTH's Discussions on Twitter

Compare HOTH with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
HOTH
Hoth Therapeutics Inc
1.35 17.70M 0 -7.51M -8.02M -1.32
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
478.10 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
574.13 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
327.25 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
569.22 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.85 29.19B 3.81B -644.79M -669.77M -6.24

Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-15-19 Initiated The Benchmark Company Speculative Buy

Hoth Therapeutics Inc Stock (HOTH) Latest News

pulisher
08:53 AM

Hoth Therapeutics Inc. Stock Analysis and ForecastHigh-yield trading alerts - Autocar Professional

08:53 AM
pulisher
Jul 22, 2025

Hoth Therapeutics shares fall 1.52% intraday after signing VA research deal to advance GDNF as breakthrough therapy for obesity and fatty liver. - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

Hoth Therapeutics partners with VA to test GDNF therapy for obesity By Investing.com - Investing.com South Africa

Jul 22, 2025
pulisher
Jul 22, 2025

Hoth Therapeutics partners with VA to test GDNF therapy for obesity - Investing.com Australia

Jul 22, 2025
pulisher
Jul 22, 2025

New Weight Loss Drug Challenger GDNF Takes On Semaglutide in Landmark VA Obesity Study - Stock Titan

Jul 22, 2025
pulisher
Jul 22, 2025

Why Hoth Therapeutics Inc. stock attracts strong analyst attentionElite Investor Club - Newser

Jul 22, 2025
pulisher
Jul 21, 2025

Is Hoth Therapeutics Inc. a good long term investmentUnprecedented growth rates - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

What analysts say about Hoth Therapeutics Inc. stockFree Stock Selection - Autocar Professional

Jul 21, 2025
pulisher
Jul 20, 2025

What drives Hoth Therapeutics Inc. stock pricePowerful profit generation - printweek.in

Jul 20, 2025
pulisher
Jul 15, 2025

How Hoth Therapeutics Inc. stock performs during market volatilitySwing Trade Signals - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Hoth Therapeutics Inc. stock price move sharplyDaily Volume Leaders - Newser

Jul 15, 2025
pulisher
Jul 05, 2025

Hoth Therapeutics (NASDAQ:HOTH) Upgraded by Wall Street Zen to Hold Rating - Defense World

Jul 05, 2025
pulisher
Jun 25, 2025

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market | Daily Courier - FinancialContent

Jun 25, 2025
pulisher
Jun 24, 2025

Hoth Therapeutics Advances HT-001 for Cancer Treatment - TipRanks

Jun 24, 2025
pulisher
Jun 24, 2025

HT-001's Breakthrough in Oncology Supportive Care: A Game-Changer for Hoth Therapeutics? - AInvest

Jun 24, 2025
pulisher
Jun 24, 2025

Hoth Therapeutics stock rises after positive Phase 2a trial results By Investing.com - Investing.com UK

Jun 24, 2025
pulisher
Jun 23, 2025

Leading Cancer Experts Reveal Phase 2 Data for Revolutionary Skin Toxicity Treatment HT-001 - Stock Titan

Jun 23, 2025
pulisher
Jun 20, 2025

Hoth Therapeutics Regains Nasdaq Compliance on June 18 - TipRanks

Jun 20, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics reports positive preclinical safety data for HT-KIT By Investing.com - Investing.com South Africa

Jun 18, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics Regains Nasdaq Compliance - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics regains Nasdaq compliance after meeting minimum bid - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics Just Cleared Critical Nasdaq Hurdle: What This Means for Its $1B+ Biotech Pipeline - Stock Titan

Jun 18, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT Dose-Dependent Liver Activity with No Observed Toxicity Supports Ind Pathway - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics (HOTH) Reports Promising Preclinical Outcomes for Cancer Drug | HOTH Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Cancer Drug Breakthrough: Hoth's HT-KIT Achieves Perfect Safety Profile Ahead of Clinical Trials - Stock Titan

Jun 18, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics regains Nasdaq compliance after meeting minimum bid By Investing.com - Investing.com India

Jun 18, 2025
pulisher
Jun 16, 2025

Market Momentum Report: Hoth Therapeutics Inc (HOTH)’s Negative Close at 1.30 - DWinneX

Jun 16, 2025
pulisher
Jun 16, 2025

Hoth Therapeutics Joins 20,000 Biotech Leaders at World's Largest Industry Convention - Stock Titan

Jun 16, 2025
pulisher
Jun 13, 2025

Hoth Therapeutics (HOTH) Secures Patent for HT-KIT Platform in J - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Hoth Therapeutics (NASDAQ:HOTH) Receives “Buy” Rating from D. Boral Capital - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

Hoth Therapeutics secures Japanese patent for mast cell disease treatment By Investing.com - Investing.com South Africa

Jun 12, 2025
pulisher
Jun 12, 2025

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases - MarketScreener

Jun 12, 2025
pulisher
Jun 12, 2025

Hoth Therapeutics secures Japanese patent for mast cell disease treatment - Investing.com

Jun 12, 2025
pulisher
Jun 12, 2025

Hoth Therapeutics Secures 15-Year Japanese Patent Protection for Revolutionary Mast Cell Disease Platform - Stock Titan

Jun 12, 2025
pulisher
Jun 12, 2025

Hoth Therapeutics (HOTH) Receives 'Buy' Rating from D. Boral Capital | HOTH Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Hoth Therapeutics plans expanded access program for cancer skin toxicity drug - Investing.com India

Jun 12, 2025
pulisher
Jun 11, 2025

Hoth Therapeutics plans expanded access program for cancer skin toxicity drug By Investing.com - Investing.com South Africa

Jun 11, 2025
pulisher
Jun 11, 2025

Hoth Therapeutics, Inc. Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities - MarketScreener

Jun 11, 2025
pulisher
Jun 11, 2025

Hoth Therapeutics Launches Expanded Access Initiative For HT-001 - MarketScreener

Jun 11, 2025
pulisher
Jun 11, 2025

HOTH Seeks Expanded Access for HT-001 to Address Skin Toxicities | HOTH Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Hoth Expands Access to Cancer Skin Toxicity Treatment HT-001 in Phase 2a Success | HOTH Stock News - Stock Titan

Jun 11, 2025
pulisher
Jun 05, 2025

Hoth Therapeutics advances with HT-001 oncology skin care treatment By Investing.com - Investing.com South Africa

Jun 05, 2025
pulisher
Jun 05, 2025

Hoth Therapeutics advances with HT-001 oncology skin care treatment - Investing.com Australia

Jun 05, 2025
pulisher
Jun 05, 2025

Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities - PR Newswire

Jun 05, 2025

Hoth Therapeutics Inc Stock (HOTH) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$22.89
price up icon 5.00%
$35.97
price down icon 0.42%
$102.81
price down icon 0.20%
$27.68
price up icon 4.45%
$113.60
price up icon 1.92%
biotechnology ONC
$295.07
price down icon 0.16%
Cap:     |  Volume (24h):